Revised prices of anti-cancer medicines take effect from 9 November 2026; reduction in MRP reported in 1,031 formulations, with estimated annual savings to consumers of Rs 3,502.31 crore
The revised prices of the 137 anti-cancer drugs on whose MRP the National Pharmaceutical Pricing Authority (NPPA) capped trade margins, on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS), will come into effect from 9 November 2026, the Department of Pharmaceuticals said on 7 November 2026. As on date, 76 pharmaceutical companies have reported revised MRP for 1,225 anti-cancer formulations covering 121 drugs; reduction in MRP has been reported in 1,031 formulations, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%. According to the release, as a result of the price reductions to be effected from 9 November 2026, the estimated annual savings to consumers would be Rs 3,502.31 crore. Of the 137 identified anti-cancer drugs, 10-15 are yet to be launched in India, but Trade Margin Rationalization (TMR) will apply to them also as and when they are launched. The notification SO 5690 (E) dated 17 October 2026 will remain in force until further orders; manufacturers can avail annual price increase in accordance with Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, subject to continued compliance with the maximum permissible trade margin of 30%. Every retailer, dealer, hospital and institution is required to prominently display the revised MRP list of anti-cancer medicines on their websites and in their premises, and State Drug Controllers will monitor compliance by manufacturers, dealers, hospitals and medical institutions. Consumers can check the applicable prices through the Pharma Sahi Daam mobile application and the NPPA website and report any non-compliance or violation of the revised prices to NPPA, including on the helpline 1800-11-1255.
Drafted with AI assistance from the official PIB release linked above and checked against it by a second AI pass. Not line-edited by a human. Published by Mahesh Srivastava, who corrects any error you report.
Learning context
On 8 October 2026, the Department of Pharmaceuticals said the Government had approved a cap on the margins charged in the supply and sale of non-scheduled anti-cancer drugs, limiting them to 30% of the Maximum Retail Price (MRP); the measure was then expected to reduce medicine prices by up to 70% and help cancer patients save Rs 2,500 crore annually. Essential cancer medicines in the scheduled list are already subject to government-set ceiling prices; the decision extended price protection to non-scheduled cancer medicines by limiting the margins added before they reach patients. An expert committee under the Directorate General of Health Services (DGHS) was to finalise the list of medicines to be covered, after which NPPA would take a decision and issue the notification. According to that release, NPPA's analysis of market data found an average price mark-up of approximately 170% on non-scheduled anti-cancer medicines, reaching 700% or more in some cases. It recalled that in February 2019, on the Government's direction, NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013; that decision reduced MRPs by up to 91%, with reported annual savings of Rs 984 crore across 526 brands.
Check yourself: in February 2019, on how many selected non-scheduled anti-cancer drugs did NPPA cap trade margins, and under which paragraph of the Drugs (Prices Control) Order, 2013?
42; Paragraph 19.
Revision task: from this release, note the date from which the revised prices take effect, the number of companies, formulations and drugs reported, the formulations showing a reduction, the brands with above half their MRP cut and the highest reduction, the estimated annual savings, the notification number, the maximum permissible trade margin, and how consumers can check prices and complain; from the note, the cap the Government approved in October 2026, the saving expected then, the average mark-up NPPA found and the February 2019 decision. Keep apart the savings estimated in this release and the saving expected when the cap was approved.
Test yourself
According to the Department of Pharmaceuticals (7 November 2026), in how many anti-cancer formulations has a reduction in MRP been reported ahead of the revised prices taking effect from 9 November 2026?
Show the answer
Answer: 1,031
As on date, 76 pharmaceutical companies have reported revised MRP for 1,225 anti-cancer formulations covering 121 drugs, and reduction in MRP has been reported in 1,031 formulations, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%. The estimated annual savings to consumers would be Rs 3,502.31 crore.
Read the daily collection → · Editorial standards & corrections